Sign in
WithdrawnEarly phase 1

MR and Inflammation After Preeclampsia

Key facts

Who runs it
Anna Stanhewicz, PhD
Where
Iowa City, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
17 Dec 2025
Expected to end
1 Feb 2029
Type of study
Interventional
Treatments tested
  • Eplerenone
Record updated
29 October 2026
Why it stopped
Trainee project; study never initiated

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • women who had preeclampsia and women who did not have preeclampsia
  • 12 weeks to 5 years postpartum
  • 18-45 years old

Who cannot take part

  • current antihypertensive medication
  • statin or other cholesterol-lowering medication
  • history of hypertension or metabolic disease before pregnancy
  • history of gestational diabetes
  • history of gestational hypertension without preeclampsia
  • skin diseases
  • allergy to materials used during the experiment.(e.g. latex),
  • known allergy to study drugs or salt-supplement
  • current tobacco use
  • currently pregnant
  • body mass index less than 18.5 kg/m2

Where in United States

  • University of IowaIowa City, United States

About the trial

What the trial wants to find out

The purpose of this investigation is to examine the role of inappropriate mineralocorticoid receptor activation in endothelial dysfunction and vascular inflammation in otherwise healthy women with a history of preeclampsia. The main questions it aims to answer are:

Read full original descriptionShow less

1. Does overactivation of the mineralocorticoid receptor contribute to reduced endothelial function in women who had preeclampsia? 2. To what extent does the mineralocorticoid receptor mediated exaggerated production of inflammatory cytokines in immune cells from women who had preeclampsia?

Participants will visit the research laboratory for 2 experimental visits:

* Visit 1: Skin blood flow will be measured using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) to examine blood vessels in a nickel-sized area of the skin. * Visit 2: Endothelial cells will be collected from an antecubital vein.

The group in the trial

  • Assessment of microvascular functionTreatment being tested

    The investigators use intradermal microdialysis to deliver eplerenone and L-NAME to the cutaneous microvasculature

    Treatment: Eplerenone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Contribution of Mineralocorticoid Receptor Signaling to Vascular Dysfunction & Aberrant Inflammation After Preeclampsia
Record updated
29 October 2026